Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(6):836–843. doi: 10.1054/bjoc.2000.1666

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

Y Yasuda 1, T Musha 2, H Tanaka 2, Y Fujita 1, H Fujita 3, H Utsumi 4, T Matsuo 1, S Masuda 5, M Nagao 5, R Sasaki 5, Y Nakamura 2
PMCID: PMC2363820  PMID: 11259101

Abstract

We have recently shown that malignant tumours from the ovary and uterus expressed erythropoietin (Epo) and its receptor (EpoR), and that deprivation of Epo signal in tumour blocks induced death of malignant cells and capillary endothelial cells in vitro (Yasuda et al, submitted). These in vitro results prompted us to examine the effect of Epo-signal withdrawal on tumours in vivo. RT-PCR analysis demonstrated the expression of mRNAs for Epo and EpoR in the transplants of uterine and ovarian tumours in nude mice. Then we injected locally anti-Epo antibody or soluble form of EpoR into the transplants. At 12 h, 1, 7 or 14 days after the injection, all transplants were resected and examined macro- and microscopically. Tumour size was reduced in Epo signal-deprived transplants. Immunohistochemical examinations revealed destruction of Epo-responding malignant and capillary endothelial cells through apoptotic death. The degree of tumour regression correlated well with the dose and frequency of the injections. Control xenografts with saline injection or needle insertion showed well-developed tumour masses. This Epo response pathway will have profound implications for our understanding of the development and progression of malignant tumours and for the use of Epo-signal deprivation as an effective therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: erythropoietin mRNA, erythropoietin receptor mRNA, malignant cells, capillary, apoptosis

Full Text

The Full Text of this article is available as a PDF (945.5 KB).

Footnotes

The experiments described in this paper were performed according to UKCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anagnostou A., Lee E. S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5978–5982. doi: 10.1073/pnas.87.15.5978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E. S., Kessimian N., Noguchi C. T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974–3978. doi: 10.1073/pnas.91.9.3974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bunn H. F., Poyton R. O. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev. 1996 Jul;76(3):839–885. doi: 10.1152/physrev.1996.76.3.839. [DOI] [PubMed] [Google Scholar]
  4. Carlini R. G., Reyes A. A., Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995 Mar;47(3):740–745. doi: 10.1038/ki.1995.113. [DOI] [PubMed] [Google Scholar]
  5. Goto M., Murakami A., Akai K., Kawanishi G., Ueda M., Chiba H., Sasaki R. Characterization and use of monoclonal antibodies directed against human erythropoietin that recognize different antigenic determinants. Blood. 1989 Sep;74(4):1415–1423. [PubMed] [Google Scholar]
  6. Guillemin K., Krasnow M. A. The hypoxic response: huffing and HIFing. Cell. 1997 Apr 4;89(1):9–12. doi: 10.1016/s0092-8674(00)80176-2. [DOI] [PubMed] [Google Scholar]
  7. Haller H., Christel C., Dannenberg L., Thiele P., Lindschau C., Luft F. C. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996 Aug;50(2):481–488. doi: 10.1038/ki.1996.339. [DOI] [PubMed] [Google Scholar]
  8. Ihle J. N. Cytokine receptor signalling. Nature. 1995 Oct 19;377(6550):591–594. doi: 10.1038/377591a0. [DOI] [PubMed] [Google Scholar]
  9. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992 Apr;72(2):449–489. doi: 10.1152/physrev.1992.72.2.449. [DOI] [PubMed] [Google Scholar]
  10. Komatsu N., Fujita H. Induced megakaryocytic maturation of the human leukemia cell line UT-7 results in down-modulation of erythropoietin receptor gene expression. Cancer Res. 1993 Mar 1;53(5):1156–1161. [PubMed] [Google Scholar]
  11. Krantz S. B. Erythropoietin. Blood. 1991 Feb 1;77(3):419–434. [PubMed] [Google Scholar]
  12. Lin C. S., Lim S. K., D'Agati V., Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996 Jan 15;10(2):154–164. doi: 10.1101/gad.10.2.154. [DOI] [PubMed] [Google Scholar]
  13. Masuda S., Nagao M., Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol. 1999 Jul;70(1):1–6. [PubMed] [Google Scholar]
  14. Maxwell P. H., Pugh C. W., Ratcliffe P. J. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2423–2427. doi: 10.1073/pnas.90.6.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nagao M., Masuda S., Abe S., Ueda M., Sasaki R. Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor. Biochem Biophys Res Commun. 1992 Oct 30;188(2):888–897. doi: 10.1016/0006-291x(92)91139-h. [DOI] [PubMed] [Google Scholar]
  16. Ovejera A. A., Houchens D. P., Barker A. D. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci. 1978 Jan-Feb;8(1):50–56. [PubMed] [Google Scholar]
  17. Porter D. L., Goldberg M. A. Regulation of erythropoietin production. Exp Hematol. 1993 Mar;21(3):399–404. [PubMed] [Google Scholar]
  18. Ratcliffe P. J., O'Rourke J. F., Maxwell P. H., Pugh C. W. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol. 1998 Apr;201(Pt 8):1153–1162. doi: 10.1242/jeb.201.8.1153. [DOI] [PubMed] [Google Scholar]
  19. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., Nico B., Roncali L., Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999 Apr 15;93(8):2627–2636. [PubMed] [Google Scholar]
  20. Sadamoto Y., Igase K., Sakanaka M., Sato K., Otsuka H., Sakaki S., Masuda S., Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998 Dec 9;253(1):26–32. doi: 10.1006/bbrc.1998.9748. [DOI] [PubMed] [Google Scholar]
  21. Sakanaka M., Wen T. C., Matsuda S., Masuda S., Morishita E., Nagao M., Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4635–4640. doi: 10.1073/pnas.95.8.4635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sawyer S. T., Hankins W. D. The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6849–6853. doi: 10.1073/pnas.90.14.6849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Semenza G. L. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med. 1998 Mar;131(3):207–214. doi: 10.1016/s0022-2143(98)90091-9. [DOI] [PubMed] [Google Scholar]
  24. Wenger R. H., Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem. 1997 Jul;378(7):609–616. [PubMed] [Google Scholar]
  25. Wu H., Liu X., Jaenisch R., Lodish H. F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995 Oct 6;83(1):59–67. doi: 10.1016/0092-8674(95)90234-1. [DOI] [PubMed] [Google Scholar]
  26. Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K., Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem. 1996 Jul 15;239(2):494–500. doi: 10.1111/j.1432-1033.1996.0494u.x. [DOI] [PubMed] [Google Scholar]
  27. Yasuda Y., Masuda S., Chikuma M., Inoue K., Nagao M., Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998 Sep 25;273(39):25381–25387. doi: 10.1074/jbc.273.39.25381. [DOI] [PubMed] [Google Scholar]
  28. Yasuda Y., Nishi N., Takahashi J. A., Konishi H., Ohara I., Fujita H., Ohta M., Itoh N., Hatanaka M., Tanimura T. Induction of avascular yolk sac due to reduction of basic fibroblast growth factor by retinoic acid in mice. Dev Biol. 1992 Apr;150(2):397–413. doi: 10.1016/0012-1606(92)90251-b. [DOI] [PubMed] [Google Scholar]
  29. Youssoufian H., Longmore G., Neumann D., Yoshimura A., Lodish H. F. Structure, function, and activation of the erythropoietin receptor. Blood. 1993 May 1;81(9):2223–2236. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES